In conclusion, we found that m6A methylation regulator YTHDC2 may become a potential marker for molecular diagnosis and prognosis of HNSCC through this study, and will also provide a new target for the development of clinical molecular targeted therapy drugs. The gene discussed is YTHDC2; the disease is head and neck squamous cell carcinoma.